NASDAQ:KRON Kronos Bio Q4 2024 Earnings Report $0.72 +0.01 (+1.38%) Closing price 05/7/2025 03:58 PM EasternExtended Trading$0.72 0.00 (-0.56%) As of 05/7/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Kronos Bio EPS ResultsActual EPS-$0.43Consensus EPS -$0.30Beat/MissMissed by -$0.13One Year Ago EPSN/AKronos Bio Revenue ResultsActual Revenue$2.27 millionExpected Revenue$1.00 millionBeat/MissBeat by +$1.27 millionYoY Revenue GrowthN/AKronos Bio Announcement DetailsQuarterQ4 2024Date3/18/2025TimeBefore Market OpensConference Call DateMonday, March 17, 2025Conference Call Time7:00PM ETUpcoming EarningsKronos Bio's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Kronos Bio Earnings HeadlinesKronos Bio (KRON) Projected to Post Earnings on ThursdayMay 7 at 2:49 AM | americanbankingnews.comKRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRONMay 4, 2025 | businesswire.comTrump's $500B plan is fueling these monthly dividendsSomething extraordinary happened just 24 hours after Trump returned to office... He signed a document that Wall Street executives desperately hoped would stay hidden. Inside is a $500 billion opportunity that could soon be fueling monthly dividends to everyday Americans like you.May 8, 2025 | Investors Alley (Ad)Concentra To Acquire Kronos BioMay 3, 2025 | nasdaq.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRONMay 1, 2025 | prnewswire.comKronos Bio Agrees to Be Acquired by Concentra BiosciencesMay 1, 2025 | marketwatch.comSee More Kronos Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kronos Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kronos Bio and other key companies, straight to your email. Email Address About Kronos BioKronos Bio (NASDAQ:KRON), a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.View Kronos Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Disney Stock Jumps on Earnings—Is the Magic Sustainable?Archer Stock Eyes Q1 Earnings After UAE UpdatesFord Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostPalantir Stock Drops Despite Stellar Earnings: What's Next?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release? Upcoming Earnings Enbridge (5/9/2025)Petróleo Brasileiro S.A. - Petrobras (5/12/2025)Simon Property Group (5/12/2025)JD.com (5/13/2025)NU (5/13/2025)Sony Group (5/13/2025)SEA (5/13/2025)Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)NetEase (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
